News and features

Professor Paul Workman discusses the issues facing the pharmaceutical industry – and the role that non-profit and academic organisations like the ICR can play in driving drug discovery progress – in a BBC Radio 4 special.

Distinguished ICR scientist Professor Philip Lawley died recently at the age of 84. His former ICR colleague Dr Stan Venitt, Emeritus Reader in Cancer Studies, reflects on an accomplished and dedicated man who gave the world the first convincing evidence that DNA damage was the basic cause of cancer.

The annual ICR Scientific Image Competition provides our scientists and students an opportunity to share the importance of their research through the visual means of images gathered during the research process. Looking at the winning entries in this year's competition, it is hard not to feel that you are viewing artwork.

Multiple Myeloma affects around 4000 people each year. The average survival time after diagnosis is just three to five years, so new treatment options are urgently needed

The world’s largest study into the causes of male breast cancer has found a gene that can increase the risk of the disease by up to 50 per cent.

Scientists at The Institute of Cancer Research, in conjunction with cancer drug discovery company Sareum, have shown that a new type of drug could boost the effectiveness of chemotherapy treatments for many cancer types.

A whole-genome scan to identify large-scale chromosomal damage can help doctors choose the best treatment option for children with neuroblastoma, finds a study led by the ICR.

Prostate cancer researchers at The Institute of Cancer Research, London, are launching two new collaborations that will make use of cutting-edge genetic technology to help improve patients’ treatment options, thanks to a $750,000 funding boost.

Astex, CRT and the ICR have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.

Men with prostate cancer who receive hormone therapy intermittently respond as well as those who receive it over a continuous time period, and enjoy quality-of-life benefits, according to a study published in the New England Journal of Medicine today.

A study in the New England Journal of Medicine shows the drug enzalutamide can significantly extend life and improve quality of life in men with advanced prostate cancer – the fourth time in two years that a new drug has been shown to improve overall survival.

Researchers at The Institute of Cancer Research (ICR) are investigating a new treatment that could destroy cancer cells in the abdomen by zapping them with intense soundwaves.